It's crystal ball season:

"Will Novo Nordisk end the year as Europe’s most valuable company?

Yes. In 2023, obesity treatment Wegovy became one of the most successful drug launches of all time and Denmark’s Novo overtook luxury goods group LVMH in value. But 2024 looks challenging for those selling highly priced handbags to China — while Novo’s main issue in selling highly priced obesity medication is how quickly it can produce it. After winning over patients and doctors to using its diabetes drug for obesity, Novo is now expanding access and coverage in a market where perhaps 1mn people are being treated out of a patient population of 100mn in the US and 700mn globally."
- Helen Thomas

https://www.ft.com/content/7eef99e6-6bd5-4e84-85c1-ec77cc0671af